"This is the first reported stable genetic modification of this parasite."
Researchers at Washington University School of Medicine in St. Louis have successfully engineered the human hookworm to produce and deliver a therapeutic antibody within a living host. The findings, published in Nature Communications on June 3, 2026, represent a significant breakthrough in biotechnology.
Study Details
The research team inserted a gene encoding a human single-chain antibody that neutralizes tetrodotoxin, a potent neurotoxin found in pufferfish and other marine animals. After colonizing the intestines of hamsters with the modified hookworms, the parasites secreted the antibody into the host's bloodstream.
Blood samples from hamsters with modified worms showed partial neutralization of tetrodotoxin, while blood from hamsters with unmodified worms did not.
The work was funded by the U.S. Defense Advanced Research Projects Agency (DARPA) and the Naval Information Warfare Center Pacific (NIWC Pacific) under contract number N66001-21-C-4013, and DARPA contract N660012314009.
Technical Approach
Gene-editing tools were adapted for hookworms using genomic data to identify a suitable insertion site that ensures secretion of the therapeutic protein.
The hookworm's natural biology allows it to reside in the small intestine for years without multiplying, while secreting molecules into the host's system. The platform leverages this ability to provide a controlled, long-term delivery system. If needed, the infection can be cleared with a single dose of an oral anti-parasitic drug.
Potential Applications and Next Steps
Senior author Makedonka Mitreva, PhD, noted that the approach could be optimized for higher production levels. Intestinal concentrations of therapeutic molecules are expected to be higher than those detected in circulation.
Candidate conditions for this platform include inflammatory bowel diseases (e.g., Crohn's disease, ulcerative colitis), food allergies, and any condition requiring sustained low-dose therapy.
Researchers are developing biocontainment strategies, including engineering the worms to be sterile (eggless). Safety evaluations are required before any human trials can proceed.